RESUMEN
To assess the safety of molnupiravir capsules (MOV) and the adherence of patients taking these capsules, we conducted a survey of patients who were dispensed MOV at the Maruzen Pharmacy from January 1st to September 30th, 2022. In the survey, a sample of 134 patients were requested to complete a questionnaire, from whom we received 56 responses (response rate: 41.8%). Among the respondents, 11 (19.6%) failed to complete their medication, and those aged 60 years or older tended to have poor adherence (P<0.001). Apart from age, we detected no statistical differences with respect to other assessed factors (gender, capsule size, occurrence of side effects, and evaluation of pharmacist’s explanations). Side effects were reported by 11 individuals (19.6%) taking the drug, although these were mainly consistent with those that have been reported in clinical trials. In addition, 20 individuals (35.7%) experienced COVID-19 after-effects after taking MOV. When requested to evaluate pharmacies and pharmacists, five individuals (8.9%) reported feeling dissatisfied. Although the results obtained in this survey are based on a limited number of patients, they do reveal a concerning lack of adherence among patients over 60 years of age; and there are needs for future improvements in the size of MOV capsules.
RESUMEN
In recent years much more attention has gained by antiviral drugs because of severe acute respiratory syndrome coronavirus-2 (SARS-CoV) infection. Molnupiravir is one of the favorable drugs for SARS-CoV-2 treatment. The present study aimed to develop and validate a simple, rapid, stable, selective, sensitive, accurate, robust, and economical RP-HPLC method for determining molnupiravir in its capsule dosage form. The chromatographic separation was achieved on inert sustain C18 column (250 mm x 4.6 mm x 5 ?) at 40°. Isocratic elution was performed with 25 mM KH2PO4 buffer (pH 3.0) and methanol (60:40 v/v) as mobile phase at flow rate of 1.0 mL/min with 50 ?L injection volume. The detection was conceded out at 242 nm. The developed RP-HPLC method yielded a suitable retention time of 4.2 minutes for molnupiravir. The developed method was validated according to the International Council on Harmonization (ICH) guidelines and established to be linear in the range of 10 to 70 ?g/mL with a linear regression coefficient of 0.9993. The %RSD for the method precision and system precision was found to be less than 2.0%. The %assay of the formulation is 101.52%. The LoD and LoQ were found to be 0.25 and 0.75 ?g/mL, respectively. The specificity of the method established using forced degradation studies in which the drug is subjected to the stressed conditions such as thermal, acidic, basic oxidative and photolytic degradation. The developed and validated RP-HPLC method for molnupiravir takes short time and can be used for routine quality analysis of marketed Molnupiravir in capsule dosage form.
RESUMEN
The WHO Therapeutics and COVID-19: living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges. This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.